PD-L1 expressed by T cells provides backward and forward signals to restrain both innate and adaptive immune responses in tumor tissues.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Emerging phagocytosis checkpoints in cancer immunotherapy
Signal Transduction and Targeted Therapy Open Access 07 March 2023
-
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Cancer Immunology, Immunotherapy Open Access 06 October 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dong, H. & Chen, L. J. Mol. Med. 81, 281–287 (2003).
Diskin. B. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-0620-x (2020).
Dong, H., Zhu, G., Tamada, K. & Chen, L. Nat. Med. 5, 1365–1369 (1999).
Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. Annu. Rev. Immunol. 26, 677–704 (2008).
Herbst, R. S. et al. Nature 515, 563–567 (2014).
Tang, H. et al. J. Clin. Invest. 128, 580–588 (2018).
Kamada, T. et al. Proc. Natl Acad. Sci. USA 116, 9999–10008 (2019).
Pulko, V. et al. J. Immunol. 187, 5606–5614 (2011).
Dong, H. et al. J. Clin. Invest. 111, 363–370 (2003).
Saha, A. et al. J. Clin. Invest. 126, 2642–2660 (2016).
Tu, X. et al. Mol. Cell 74, 1215–1226.e4 (2019).
Chang, C. H. et al. Cell 162, 1229–1241 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Johnson, R.M.G., Wen, T. & Dong, H. Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nat Immunol 21, 365–366 (2020). https://doi.org/10.1038/s41590-020-0599-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-020-0599-3
This article is cited by
-
Emerging phagocytosis checkpoints in cancer immunotherapy
Signal Transduction and Targeted Therapy (2023)
-
Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8+IFN-γ+ T cells in atherosclerosis
Inflammation Research (2023)
-
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Cancer Immunology, Immunotherapy (2021)